Magnetic particle micro-fluidic biochip for cardio-pulmonary function marker and detection method

Abstract

The invention relates to a magnetic particle micro-fluidic biochip for cardio-pulmonary function markers, and belongs to the technical field of POCT detection. The micro-fluidic biochip comprises a PCB, the PCB is provided with a micro-fluidic channel , a biosensor is arranged in the micro-fluidic channel and comprises a wafer platform and sample application antibodies coated on the wafer platform, the sample application antibodies, magnetic bead coupling antibodies and marker protein can form an immune complex, the concentration of the marker protein is judged by measuring the strength of themagnetic resistance signal on the complex on the wafer platform, and the sample application antibodies are antibodies for the six cardio-pulmonary function markers of CTI, CK-MB, MYO, D-Dime, NT-proBNP and hs-CRP. The micro-fluidic biochip is characterized in tha, magnetic beads have relatively larger specific surface area, more protein/antibodies are combined, and therefore the detection sensitivity is improved. The invention further provides a detection method applying the biochip. The detection method has the advantages that the cardiac markers of myocardial infarction, congestive heart failure and pulmonary embolism can be simultaneously and quantitatively detected, in addition, the lower limit of detection is improved, and the missing detection and false negative phenomena are effectively avoided.

Description

technical field [0001] The invention relates to a biochip, which is mainly used for detecting six markers of heart and lung function in blood samples. The invention also provides a detection method using the biochip, which belongs to the technical field of POCT detection. Background technique [0002] Cardiovascular disease is a serious disease that endangers human health and life, and has become the number one killer of human health in the 21st century. According to the "China Cardiovascular Disease Report 2015" and "China Cardiovascular Disease Report 2016" compiled by the National Center for Cardiovascular Diseases, the number of patients with cardiovascular diseases in my country is still growing rapidly. According to statistics, the number of patients with cardiovascular disease was 290 million in 2014, and this number has climbed to 290 million by 2015. According to the report estimates, about 3.5 million people die of cardiovascular disease in my country every year, ...

AI Technical Summary

Problems solved by technology

[0008] The first-generation detection technology competition method (radioimmunoassay, RIA): There are many factors affected, and the RIA sample requires a large amount. Because extraction is usually required before detection, it not only increases the operation steps, but also because the recovery rate of extraction is usually Only 80% to 90%, the coefficient of variation (CV) is relatively large, which reduces the precision of detection;

[0009] The second-generation detection method non-competitive method (radioimmunoassay, RIA): immunoassay using double-antibody sandwich, no extraction, high antibody specificity, its sensitivity, precision and specificity are better than competitive methods, but time-consuming Still long and difficult to apply to automation;

[0010] The third-generation detection method enzyme immunoassay, stationary phase immunochromatography: the double antibody plus core method immunoassay solid phase chroma

Images